Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 11/20 | 0.40 |
| ▸ | NMT2 | O60551 | 10/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | NPY4R | P50391 | 2/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20889009 | 0.91 | NMT1 (0.41) | NMT1NMT2TLR2PTGS1PTGS2 | |
| SCHEMBL20340675 | 0.91 | NMT1 (0.43) | NMT1NMT2TLR2PTGS1PTGS2 | |
| SCHEMBL17722904 | 0.87 | NMT1 (0.45) | NMT1NMT2TLR2PTGS1PTGS2 | |
| SCHEMBL22668934 | 0.85 | NPY4R (0.38) | NMT1NMT2TLR2PTGS1PTGS2 | |
| SCHEMBL19681343 | 0.85 | NMT1 (0.46) | NMT1NMT2TLR2PTGS1PTGS2 | |
| SCHEMBL24780979 | 0.84 | NMT1 (0.44) | NMT1NMT2TLR2NPY4RNPY1R | |
| SCHEMBL22668929 | 0.83 | PTGS1 (0.44) | NMT1NMT2PTGS1PTGS2NPY4R | |
| SCHEMBL20889000 | 0.83 | NMT1 (0.46) | NMT1NMT2TLR2NPY4RNPY1R | |
| SCHEMBL23436462 | 0.83 | NMT1 (0.46) | NMT1NMT2TLR2NPY4RNPY1R | |
| SCHEMBL19681474 | 0.81 | NPY5R (0.39) | NMT1NMT2PTGS1PTGS2NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| US-10195209-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | NMT1 1208/4885NMT2 1110/4885TLR2 2881/4885 |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | CD2, CD2BP2, CD22 | NMT1 1317/4885NMT2 1971/4885TLR2 1223/4885 |
| US-10195209-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | NMT1 1208/4885NMT2 1110/4885TLR2 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.